Vice President, Regulatory Affairs STERIS Corporation, Ohio, United States
The session will highlight recent findings for MDUFA V (Fiscal Years 2022-2027) and some background on the MDUFA VI negotiations and how they may impact your US regulatory strategies. Hear both Industry Advocacy and FDA leaders describe the process and the outcomes.
